Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.38 |
| ▸ | SQLE | Q14534 | 6/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4894351 | 1.00 | KMT2A (0.42) | KMT2AFNTAFNTBMAPTMEN1 | |
| SCHEMBL4894340 | 1.00 | KMT2A (0.42) | KMT2AFNTAFNTBMAPTMEN1 | |
| SCHEMBL17363846 | 0.83 | KMT2A (0.43) | KMT2AFNTAFNTBMAPTMEN1 | |
| SCHEMBL17363847 | 0.83 | KMT2A (0.43) | KMT2AFNTAFNTBMAPTMEN1 | |
| SCHEMBL794794 | 0.80 | KMT2A (0.54) | KMT2AFNTAFNTBMAPTMEN1 | |
| SCHEMBL794795 | 0.80 | KMT2A (0.54) | KMT2AFNTAFNTBMAPTMEN1 | |
| SCHEMBL4716275 | 0.76 | FNTA (0.42) | KMT2AFNTAFNTBMAPTMEN1 | |
| SCHEMBL14753530 | 0.76 | KMT2A (0.43) | KMT2AFNTAFNTBMAPTMEN1 | |
| SCHEMBL21638729 | 0.74 | KDM4E (0.32) | KMT2AKDM4E | |
| SCHEMBL2524503 | 0.74 | KMT2A (0.50) | KMT2AFNTAFNTBMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201510-B2 | Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| US-20080286209-A1 | Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201510-B2 | Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure | ADH1C, ADH1A, CHRNA10 | KMT2A 1291/4885FNTA 56/4885FNTB 68/4885 |
| US-20080286209-A1 | Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure | PNMT, ADH1A, CHRNA10 | KMT2A 1287/4885FNTA 45/4885FNTB 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.